VANCOUVER, British Columbia, Feb. 21, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188…


Previous articleThe Medical Potential of Psychedelics: A View from the European Union
Next articlePT391 – MDMA-Assisted Psychotherapy For Fibromyalgia and Other Central Sensitization Syndromes